SEPN
Septerna
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
SEPN Profile
Septerna, Inc.
A biotechnology company utilizes its proprietary Native Complex Platform ? Technology has ushered in a new era of orally administered small molecule drugs using G protein coupled receptors (GPCRs).
Biological Technology
Invalid Date
10/25/2024
NASDAQ Stock Exchange
75
12-31
Common stock
250 East Grand Avenue, South San Francisco, California 94080
--
Septerna, Inc., was incorporated in Delaware in December 2019 under the name GPCR NewCo, Inc. In June 2021, they changed their name to Septerna, Inc. The company is a clinical-stage biotechnology company that has ushered in a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, powered by its proprietary Native Complex PlatformTM. Their industrial-scale platform aims to unlock the full potential of GPCR therapies and discover and develop their deep pipeline of product candidates, initially focusing on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.